Skip to content
Evigrade
CriticalOpioid analgesic with dual mechanism×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative

Updated · Methodology

Mechanism

Tapentadol is an opioid analgesic: it stimulates mu-opioid receptors and also inhibits noradrenaline reuptake (tapentadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO), the enzyme that breaks down serotonin, noradrenaline and dopamine (tranylcypromine SmPC, AEMPS, section 5.1). According to the Spanish tapentadol SmPC, MAO inhibitors can raise synaptic noradrenaline concentrations even further, which may lead to cardiovascular adverse reactions such as hypertensive crisis (tapentadol SmPC, AEMPS, section 4.5). According to the US tapentadol label, interactions of MAO inhibitors with opioids may present as serotonin syndrome or opioid toxicity (tapentadol label, US Food and Drug Administration, FDA, section 7). The US tranylcypromine label names both main risks for tapentadol: hypertensive reactions and serotonin syndrome (tranylcypromine FDA label, section 7.1).

Symptoms

The documents do not describe how this particular combination presents: they contraindicate it pre-emptively. Possible outcomes are a hypertensive crisis due to higher noradrenaline concentrations (tapentadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5), serotonin syndrome, or opioid toxicity with respiratory depression and coma (tapentadol label, US Food and Drug Administration, FDA, section 7). Serotonin syndrome presents with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (overactive reflexes, poor coordination), nausea, vomiting and diarrhoea. It can be fatal and usually starts within several hours to a few days of combined use, but may start later (FDA tapentadol label, section 5.7). A hypertensive crisis presents with an occipital headache, palpitations, neck stiffness or soreness, nausea or vomiting, sweating, dilated pupils, sensitivity to light, shortness of breath or confusion, sometimes with constricting chest pain and seizures. Intracranial bleeding, sometimes fatal, has been reported with the rise in blood pressure (tranylcypromine FDA label, section 5.2).

Management

The combination is contraindicated. The US tapentadol label prohibits taking tapentadol with monoamine oxidase (MAO) inhibitors or within 14 days of stopping them, and names tranylcypromine among the examples (tapentadol label, US Food and Drug Administration, FDA, sections 4 and 7). The US tranylcypromine label contraindicates tapentadol by name (tranylcypromine FDA label, sections 4.1 and 7.1). The Spanish documents are milder: the tapentadol summary of product characteristics (SmPC) advises avoiding tapentadol in patients who take MAO inhibitors or have taken them in the last 14 days (tapentadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The tranylcypromine SmPC does not name tapentadol. Start tapentadol no earlier than 14 days after stopping tranylcypromine (tapentadol SmPC, AEMPS, section 4.5; FDA tapentadol label, sections 4 and 7), and do not start an MAO inhibitor while the patient is taking tapentadol (FDA tapentadol label, section 17). If an opioid is needed urgently, the US tapentadol label advises treating pain with other opioids, such as oxycodone, hydrocodone, oxymorphone or buprenorphine. Start with test doses, titrate small doses frequently and closely monitor blood pressure and signs of central nervous system and respiratory depression (FDA tapentadol label, section 7). With buprenorphine, the Spanish tranylcypromine SmPC states that serotonin syndrome cannot be ruled out, so monitor the patient carefully, especially at the start of treatment and when the dose is increased (tranylcypromine SmPC, AEMPS, section 4.4). If serotonin syndrome is suspected, stop tapentadol (FDA tapentadol label, section 5.7), stop tranylcypromine and any concomitant serotonergic drugs at once and start supportive symptomatic treatment (tranylcypromine FDA label, section 5.3). If palpitations, headache or other early signs of a hypertensive crisis appear, interrupt treatment and assess the patient at once (tranylcypromine FDA label, section 5.2). Before planned surgery with anaesthetics or certain analgesics, consider stopping tranylcypromine 14 days in advance (tranylcypromine SmPC, AEMPS, section 4.5). The US label recommends stopping it at least 10 days before elective surgery (tranylcypromine FDA label, section 5.6).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Tapentadol

Other interactions with Tranylcypromine